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argeted disruption of 
 
core binding factor 
 
 
 
1 (Cbfa1)
 
showed that Cbfa1 is an essential transcription factor
in osteoblast differentiation and bone formation.
 
Furthermore, both in vitro and in vivo studies showed that
Cbfa1 plays important roles in matrix production and
mineralization. However, it remains to be clariﬁed how
Cbfa1 controls osteoblast differentiation, bone formation,
 
and bone remodelling. To understand fully the physiological
functions of Cbfa1, we generated transgenic mice that
overexpressed Cbfa1 in osteoblasts using type I collagen
 
promoter. Unexpectedly, 
 
Cbfa1
 
 transgenic mice showed
osteopenia with multiple fractures. Cortical bone, which was
thin, porous, and enriched with osteopontin, was invaded by
T
 
osteoclasts, despite the absence of acceleration of osteo-
clastogenesis. Although the number of neonatal osteoblasts
 
was increased, their function was impaired in matrix
production and mineralization. Furthermore, terminally
differentiated osteoblasts, which strongly express osteocalcin,
and osteocytes were diminished greatly, whereas less
mature osteoblasts expressing osteopontin accumulated in
adult bone. These data indicate that immature organization
of cortical bone, which was caused by the maturational
blockage of osteoblasts, led to osteopenia and fragility in
transgenic mice, demonstrating that Cbfa1 inhibits osteo-
blast differentiation at a late stage.
 
Introduction
 
Bone is a mineralized tissue that is composed of an organic
 
matrix. Type I collagen constitutes 
 
 
 
95% of the organic
matrix, and the remaining 5% is composed of proteogly-
cans and noncollagenous proteins such as osteopontin and
osteocalcin. Bone formation and maintenance are carried
out by the coupled activities of osteoblasts and osteoclasts.
Osteoblasts are bone-forming cells that synthesize and
mineralize extracellular matrix, whereas osteoclasts are
bone-resorbing cells that remove mineralized matrix. Os-
teoblasts arise from multipotential mesenchymal cells and
further differentiate into bone-lining cells and osteocytes,
the latter of which are the most abundant cells in bone and
work as mechanosensors (Nijweide et al., 1996). Osteo-
clasts are derived from hematopoietic precursor cells
formed by the fusion of monocytic cells at the bone sites to
be resorbed. Dysfunction of and imbalance between them
can lead to bone metabolic disease states such as osteoporosis,
which is marked by progressive bone loss and increased risk
of fracture, or more rarely, osteopetrosis. Many factors in-
fluence the activities of these cells, and BMPs, TGF
 
 
 
s,
FGFs, and IGFs, which are known to be local regulators of
bone formation, have positive effects on osteoblast differ-
entiation. Recent studies have suggested that many of them
might target an important transcription factor, core bind-
ing factor 
 
 
 
1 (Cbfa1)*/runt-related gene (Runx)2, which
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directs a pathway in bone formation (for review see Yamagu-
chi et al., 2000).
Cbfa1 plays a pivotal role in osteogenesis (Komori and
Kishimoto, 1998). Mice heterozygously mutated in the
 
Cbfa1
 
 locus show a phenotype similar to that of cleidocra-
nial dysplasia in humans, in whom mutations of 
 
Cbfa1
 
 have
been found (Komori et al., 1997; Mundlos et al., 1997;
Otto et al., 1997). A homozygous mutation of this gene in
mice induced a complete lack of bone formation with arrest
of osteoblast differentiation (Komori et al., 1997; Otto et
al., 1997). However, the complete lack of osteoblasts and
neonatal lethality makes it difficult to examine the postnatal
function of Cbfa1 by using this knockout model. An alter-
native model, which expressed the dominant negative form
of Cbfa1 (DN-Cbfa1), developed an osteopenic phenotype
in mice and was used to indicate the indispensability of the
gene for postnatal bone formation by regulating the func-
tions of mature osteoblasts (Ducy et al., 1999). Further-
more, a large number of recent in vitro studies also implied
that Cbfa1 is a positive regulator that can upregulate the ex-
pression of bone matrix genes, including 
 
type I collagen
 
, 
 
os-
teopontin
 
, 
 
bone sialoprotein
 
, 
 
osteocalcin
 
, and 
 
fibronectin
 
. (Ban-
erjee et al., 1997; Ducy et al., 1997; Sato et al., 1998;
Harada et al., 1999; Xiao et al., 1999; Kern et al., 2001; Lee
et al., 2000; Prince et al., 2001). All of these studies have in-
dicated that Cbfa1 plays important roles in matrix forma-
tion and mineralization.
In the process of osteoblast differentiation, Cbfa1 seems
to function in the commitment of the osteoblast lineage
from multipotential mesenchymal cells because 
 
Cbfa1
 
-
deficient calvarial cells had the potential to differentiate
into both adipocytes and chondrocytes but completely
lacked the ability to differentiate into the osteoblastic lin-
eage (Kobayashi et al., 2000). However, after cells commit
to the osteoblastic lineage it remains to be clarified how
Cbfa1 operates in the process of bone formation. To un-
derstand fully the functions of Cbfa1 in the processes of
osteoblast differentiation, matrix production, and mineral-
ization, we generated transgenic mice that overexpress
Cbfa1 specifically in osteoblasts under the control of type I
collagen promoter. Unexpectedly, 
 
Cbfa1
 
 transgenic mice
showed severe osteopenia and suffered from bone fractures
within a few weeks after birth. Osteopenia and fragility of
bone were caused by the inhibition of osteoblast matura-
tion, and immature osteoblasts accumulated in the bone of
adult mice. These data indicate that Cbfa1 inhibits the late
stage of osteoblast maturation, restricting Cbfa1’s positive
function to the early differentiation stage in the process of
osteoblast development.
 
Results
 
Transgenic mice showed osteopenia with 
multiple fractures
 
The construct for 
 
Cbfa1
 
 transgenic mice was generated us-
ing the 2.3-kb proximal promoter of 
 
pro-
 
 
 
 (I) collagen
 
 gene
and type II Cbfa1 cDNA, which starts from exon 1 (Eno-
moto et al., 2000), to express Cbfa1 specifically in osteoblasts
(Fig. 1 A) (Rossert et al., 1995). We also generated 
 
 
 
-galac-
 
tosidase
 
 transgenic mice using the same pro-
 
 
 
1 (I) collagen
promoter. The promoter directed the expression of the
 
 
 
-galactosidase
 
 gene to osteoblasts and immature osteoblas-
tic cells (Fig. 1, B and C). Bone-specific expression of the
transgene was confirmed also by Northern blot analysis us-
ing 
 
Cbfa1
 
 transgenic mice (Fig. 1 D). The transgene was ex-
pressed only in bone not in other tissues including muscle,
brain, heart, kidney, thymus, liver, spleen, lung, testis, stom-
ach, skin, and cartilage.
Although transgenic mice were born normally, they
quickly started to display bone fractures (as early as 1 wk
after birth), and within 3 wk most of them suffered from
bone fracture. Bone fractures were found most frequently
in tibiae, fibulae, calcanei, and femurs, whereas fractures
in upper limbs and ribs were found also, indicating that
the skeleton of transgenic mice was extremely fragile.
Teeth of transgenic mice were also fragile and sometimes
broken. The phenotype of teeth will be described else-
where in detail. We generated seven F
 
0
 
 transgenic mice
with fractures. Although we succeeded in establishing a
Figure 1. Generation of transgenic mice. (A) Diagrams of the DNA 
constructs used to generate pro- 1 (I) collagen promoter Cbfa1 trans-
genic mice. DNA fragments covering the entire coding region of the 
mouse type II Cbfa1 isoform and 2.3 kb pro- 1 (I) collagen gene pro-
moter region were used. *SV40 splice donor/acceptor signals; **SV40 
polyadenylation signal. (B and C)  -Galactosidase staining in pro- 1 
(I) collagen promoter  -galactosidase transgenic mice at E15.5. 
(C) Longitudinal section of forelimb. Staining is observed specifically 
in osteoblasts around the diaphysis and in immature osteoblastic cells 
around the metaphysis. Sections were counterstained with eosin. 
(D) Northern blot hybridized with Cbfa1 probe. RNA was extracted 
from tissues of 4-wk-old Cbfa1 transgenic mice, and 20  g of total 
RNA was loaded per lane. St, stomach; Te, testis; Lu, lung; Sp, spleen; 
Li, liver; Th, thymus; Ki, kidney; He, heart; Br, brain; Mu, muscle; 
Bo, bone; Ca, cartilage; Sk, skin. (E) Northern blot analysis comparing 
the transgene and endogenous Cbfa1 levels of expression in long 
bones of newborn Cbfa1 transgenic mice. 20  g of total RNA was 
loaded. Bar, 100  m. 
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line from one of them, the other F
 
0
 
 mice were affected too
severely to be bred and were analyzed directly. Although
these F
 
0
 
 mice suffered from severe fractures (Fig. 2 D),
they showed phenotypes similar to the established line in
radiological, histological, and Northern blot analyses, and
the data from this line is described here in detail. The
transgene expression of the line was about five times
higher than endogenous 
 
Cbfa1
 
 expression (Fig. 1 E). The
body weight of transgenic (Tg) mice became progressively
lower than that of wild-type (WT) littermates during de-
velopment and reached nearly half of the normal average
value at 4 wk of age (Tg, male 9.4
 
   
 
0.4 g, 
 
n 
 
 
 
 15; Tg fe-
male, 9.2 
 
  
 
0.5 g,
 
 n 
 
 
 
 13; WT, male 18.1 
 
  
 
0.4 g, 
 
n 
 
 
 
61; WT, female 15.2 
 
  
 
0.4 g, 
 
n 
 
 
 
 51, 
 
p 
 
 
 
 0.01). The fra-
gility of bones and teeth seemed to cause the growth retar-
dation. The serum concentration of calcium was similar
between wild-type and transgenic mice at 6 wk of age
 
(WT, 9.5 
 
  
 
0.2 mg/dl, 
 
n 
 
 
 
 6; Tg, 9.1
 
 
 
0.2 mg/dl, 
 
n 
 
 
 
 9,
 
P 
 
  
 
0.1).
Radiological analysis showed that the whole skeleton of
transgenic mice was proportionally shorter, and their bone
was generally more radiolucent (Fig. 2, A and D). The
fracture healing was observed in tibiae, fibulae, and calca-
nei, and cortices were thinner (Fig. 2, B and C). The histo-
logical appearance of tibiae clearly showed osteopenia in
the transgenic mice (Fig. 3). The cortical bone of trans-
genic mice was porous and thinner at both 3 and 6 wk of
age. The analysis by peripheral quantitative computed to-
mography (pQCT) also showed thinner cortical bone and
enlarged marrow cavity in 3-mo-old transgenic mice (Fig.
4, A–E). The trabecular bone was decreased at 3 wk of age
but not at 6 wk of age in transgenic mice (Fig. 3). This was
also demonstrated by pQCT analyses in 3-mo-old mice,
which showed similar amounts of mineral content in the
Figure 2. Radiological analysis. (A–C) X-ray analysis 
of 6-wk-old Cbfa1 transgenic mice from the estab-
lished line. Whole skeletons of transgenic mice are 
proportionally shorter and more radiolucent (A). 
The transgenic mouse suffered from fractures in the 
tibia, fibula, and calcanei, and fracture healing is 
observed in these regions (A and B). The radiolucency 
is caused mainly by thinner cortices because meta-
physeal trabeculation is similarly observed in femurs 
(C). (D) Radiograph of 9-wk-old F0 transgenic mice. 
Whole skeletons are also more radiolucent, and 
fracture healing is observed in tibiae, fibulae, and 
calcanei in both lower limbs. WT, wild-type mouse; 
Tg, transgenic mouse.
Figure 3. Histological appearance of 
transgenic bone. Longitudinal sections 
through the proximal tibia of wild-type 
(A and C) and transgenic (B and D) mice 
at 3 (A and B) and 6 wk of age (C and D). 
Cortical bone in transgenic mice is thin 
and porous at both 3 and 6 wk of age. 
Transgenic mice show reduced trabecu-
lation at 3 wk of age but not at 6 wk of 
age. Undecalcified sections were stained 
with toluidine blue. Bar, 1 mm. 
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Figure 4. pQCT analysis. Diaphyses of femurs from 
wild-type and transgenic female mice at 3 mo of age 
were analyzed by pQCT. (A and B) pQCT images from 
wild-type (A) and transgenic (B) mice. Note the 
increased width of the marrow cavity and the 
concomitant reduction in cortical thickness in trans-
genic mice. Mineral densities are shown as different 
colors according to the standard mineral density
gradients. (C–F) Cortical thickness (C), endosteal 
circumference (D), periosteal circumference (E), and 
bone mineral density (F) were measured for wild-type 
(white bars) and transgenic (black bars) mice. Error 
bars show means   SEM (n   4). *P   0.05 and 
**P   0.01 between wild-type and transgenic mice as 
determined by one-way ANOVA. Bars, 1 mm.
 
Cortical bone was immature and invaded 
by osteoclasts
 
Osteocytes in bone increase during growth. At 6 wk of age,
both trabecular and cortical bone contained many osteocytes
in wild-type mice but had few osteocytes in transgenic mice
(Fig. 3 and Fig. 5, A and B). The drastic decrease of osteocytes
was observed until 1 yr of age (Fig. 5, C–F; unpublished data).
The decrease of osteocytes in transgenic mice is not due to cell
death, since empty lacunae, which represent the death of osteo-
cytes, were absent in bone. Numerous tartrate-resistant acid
phosphatase (TRAP)-positive osteoclasts were observed on the
surface of trabecular bone but not in cortical bone of wild-type
mice, whereas they were observed not only on trabecular bone
 
Figure 5.
 
Decreased osteocytes, osteoclast invasion, collagen 
structure, and osteopontin deposition in cortical bone of trans-
genic mice. 
 
(A and B) TRAP staining of cortical bone in tibiae of 
wild-type (A) and transgenic (B) mice at 6 wk of age. Many TRAP-
positive osteoclasts are observed in the cavities of cortical bone in 
transgenic mice (B). Note that osteocytes are diminished greatly in 
transgenic mice. (C and D) Polarized microscopy of cortical bone
in tibias of wild-type (C) and transgenic (D) mice at 3 mo of age. 
Cortical bone in transgenic mice shows the woven pattern instead 
of the lamellar collagen deposition seen in wild-type mice. (E and F)
Immunohistochemical analysis in cortical bone of wild-type (E) and 
transgenic (F) mice at 3 mo of age using antiosteopontin antibody. 
Osteopontin is deposited heavily in cortical bone of transgenic 
mice. Note that osteocytes are spaced regularly in wild-type bone, 
but a few osteocytic cells are spaced irregularly in transgenic bone. 
Bars, 100 
 
 
 
m.
 
trabecular region (WT, 0.34 
 
  
 
0.02 mg/mm; Tg, 0.43 
 
 
 
0.04 mg/mm, 
 
n 
 
 
 
 4,
 
 P 
 
  
 
0.05). Maintenance of trabecu-
lar bone and thinner porous cortical bone were observed
also in histological analyses of 3- and 8-mo-old transgenic
mice (unpublished data). 
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but also on cortical bone, especially in the cavities in transgenic
mice (Fig. 5, A and B). Polarization microscopy revealed that
cortical bone of transgenic mice at 3 mo of age was composed
mainly of immature bone, described as woven bone, in which
collagen fibers ran in all directions, instead of mature lamellar
bone, which has highly ordered parallel collagen fibers as seen
in wild-type mice (Fig. 5, C and D). The composition of bone
matrix was also different. Osteopontin protein was restricted to
trabecular bone in wild-type mice, whereas it was distributed
widely and extensively in the whole bone, including cortical
bone, in transgenic mice (Fig. 5, E and F).
 
Osteoblast function was impaired in both matrix 
production and mineralization
 
The cause of osteopenia was examined in detail by histomor-
phometrical analyses at 3 and 6 wk of age. The trabecular
bone volume (BV/TV) of transgenic mice was significantly
decreased at 3 wk of age but not at 6 wk of age (Fig. 6 A).
Although the number of osteoblasts in transgenic mice was
more than twice that in wild-type mice at both 3 and 6 wk
of age, matrix production by osteoblasts was impaired se-
verely in transgenic mice as shown by the decreased thick-
ness of newly deposited matrix (osteoid thickness; O.Th)
(Fig. 6, B–D). Osteocytes were decreased dramatically in
transgenic mice, with their number in cortical bone about
one-tenth of that in wild-type mice (Fig. 6 E). The number
of osteoclasts in the trabecular bone of transgenic mice was
equivalent to that of wild-type mice, but osteoclasts in trans-
genic mice were less activated at 6 wk of age as shown by an
 
 
 
50% decrease of osteoclast surface (Oc.S) and eroded sur-
face (ES) (Fig. 6, F–H). Therefore, the maintenance of tra-
becular bone volume in 6-wk-old transgenic mice seems to
be due to decreased osteolytic activity.
To perform kinetic analyses of bone formation and miner-
alization, calcein was injected twice at a 3-d interval in 3-wk-
old mice and a 7-d interval in 6-wk-old mice. Calcein injec-
tions formed two consecutive labels in most parts of 3- and
6-wk-old wild-type bone (Fig. 7 A). In contrast, transgenic
bone showed only a single band of labeling or dual lines with
decreased distance between them, and these bands were in-
terrupted frequently by engraved cavities (Fig. 7 B). Trabecu-
lar dynamic histomorphometry was performed on the longi-
tudinal sections of 3- and 6-wk-old bone. In transgenic mice,
the mean distances between the two labels were short at both
3 and 6 wk of age (Fig. 7 C), and the mineralizing surface
was decreased at 6 wk of age (Fig. 7 D), resulting in the sig-
nificantly decreased bone formation rate at 6 wk of age (Fig.
7 E). Cortical dynamic histomorphometry was performed on
cross sections of 3-wk-old bone. In transgenic mice, the mean
distances between the two labels in both periosteum and en-
dosteum were short (Fig. 7 F), and the mineralizing surface
in periosteum was decreased (Fig. 7 G), resulting in the sig-
nificantly decreased bone formation rates in both periosteum
and endosteum (Fig. 7 H). Further, pQCT analysis showed
that bone mineral density was decreased in the cortical bone
of transgenic mice (Fig. 4 F). These data indicate that osteo-
blast function was impaired in both matrix production and
mineralization in transgenic mice.
 
Fully differentiated osteoblasts were decreased and 
less mature osteoblasts were increased in
transgenic mice
 
Because osteoblasts were increased but their function was im-
paired severely in transgenic mice, osteoblastic markers were
investigated by in situ hybridization using probes of 
 
type I col-
lagen
 
, 
 
osteopontin
 
, and 
 
osteocalcin
 
. Mice at birth, 2 wk, 4 wk,
6 wk, 3 mo, and 8 mo of age were examined (Fig. 8; unpub-
lished data). In wild-type mice at birth, most bone was cov-
ered by type I collagen–positive and osteopontin-positive
Figure 6. Bone volume, matrix deposition, and cell parameters in Cbfa1 transgenic mice. Trabecular bone volume (BV/TV; bone volume 
over tissue volume) (A), osteoid thickness (O.Th) (B), osteoblast number (N.Ob) (C), osteoblast surface (Ob. S) (D), osteocyte number (N. Ot) 
(E), osteoclast number (N. Oc) (F), osteoclast surface (Oc. S) (G), and eroded surface (ES) (H) are compared between wild-type (white bars) 
and transgenic mice (black bars) at 3 and 6 wk of age. The analyses were done using proximal parts of tibiae at secondary spongiosa except 
osteocyte number, which was counted at cortical bone of diaphysis. Bars show means   SEM (n   4). *P   0.05 and **P   0.01 between 
wild-type and transgenic mice as determined by one-way ANOVA.162 The Journal of Cell Biology | Volume 155, Number 1, 2001
cells, but the number of osteocalcin-positive cells was very
low (Fig. 8, A, C, and E). In transgenic mice at birth, os-
teopontin was expressed strongly in type I collagen–positive
cells, but osteocalcin was barely detectable (Fig. 8, B, D, and
F). The number of type I collagen–positive cells was in-
creased by  60% in transgenic newborns compared with
their wild-type counterparts (WT, 1528   119/mm
2; Tg,
2531   155/mm
2, n   5, p   0.01). In wild-type mice, os-
teopontin-positive cells decreased gradually and osteocalcin-
positive cells increased gradually during development, with
osteocalcin-positive cells widely distributed at 3 mo of age
(Fig. 8, K and M). However, in transgenic mice osteopontin-
positive cells always covered most of the trabecular and corti-
cal bone, but osteocalcin expression was much weaker than in
their wild-type counterparts (Fig. 8, L, M, and N). Even in
8-mo-old transgenic mice, most bone was covered by os-
teopontin-positive cells, whereas only a small area of bone
was covered by osteopontin-positive cells in the wild-type
mice (unpublished data). Since osteopontin expression is de-
tected earlier than osteocalcin expression in osteoblast differ-
entiation (Yoon et al., 1987; Mark et al., 1988), these data
suggest that osteoblasts were less mature in transgenic mice.
Endogenous Cbfa1 expression was also examined using a
probe containing the 3  untranslated region, which does
not hybridize with the transgene (Fig. 8, G, H, O and P;
unpublished data). In wild-type mice, the expression pat-
tern of Cbfa1 was similar to that of osteopontin but differ-
ent from that of osteocalcin at any age, although some over-
laps of Cbfa1 and osteocalcin expression were observed,
especially at younger ages. It indicates that a major popula-
tion of Cbfa1 highly positive cells consists of less mature
osteoblasts. In transgenic mice, endogenous Cbfa1-positive
cells were increased, and the level of the expression seemed
to be upregulated.
Cbfa1 failed to induce expression of the genes related 
to bone matrix, mineralization, and osteoclastogenesis
Expression of the genes related to bone matrix proteins,
including type I collagen, osteopontin, bone sialoprotein, os-
teocalcin, and matrix metalloproteinase (MMP)13, is con-
Figure 7. Bone formation in trabecular and 
cortical bone. To assess osteoblast function 
in mineralization, wild-type and transgenic 
mice were double labeled with calcein at 3 
and 6 wk of age. (A and B) Fluorescent micro-
graphs of the two labeled mineralization 
fronts in femurs of wild-type (A) and trans-
genic (B) mice at 3 wk of age. The distances 
between the double labeling in transgenic 
mice are much less than those of wild-type 
mice. Note that wild-type bone shows a clear 
double-labeling pattern, but transgenic bone 
shows waved single and double labeling with 
interruption. Cross sections of mid-diaphyses 
of femurs are shown. (C–E) Measurement of 
mineral apposition rate (MAR) (C), mineraliz-
ing surface (MS) (D), and bone forming rate 
(BFR) (E) in trabecular bone of wild-type 
(white bars) and transgenic (black bars) mice 
at 3 and 6 wk of age. Longitudinal sections 
from proximal parts of tibiae were used for 
the analysis. (F–H) Measurement of MAR (F), 
MS (G), and BFR (H) in periosteum and 
endosteum of wild-type (white bars) and 
transgenic (black bars) mice at 3 wk of age. 
Cross sections from mid-diaphyses of femurs 
were used for the analysis. Error bars show 
means   SEM (n   4). *P   0.05 and 
**P   0.01 between wild-type and transgenic 
mice as determined by one-way ANOVA. 
Scale bar, 100  m.Osteopenia in Cbfa1 transgenic mice | Liu et al. 163
sidered to be regulated by Cbfa1 (Yamaguchi et al.,
2000). Alkaline phosphatase (ALP) is considered to be up-
regulated during osteoblast differentiation (Stein et al.,
1990). To analyze the expression of these genes, Northern
blot or reverse transcriptase (RT)-PCR analysis was per-
formed using RNA from long bones of 1-mo-old wild-type
and transgenic mice (Fig. 9). The expression of pro- 1
type I collagen was decreased slightly in transgenic mice,
whereas pro- 2 type I collagen expression was similar be-
tween wild-type and transgenic mice. The expression of
osteopontin and bone sialoprotein was increased but that of
ALP, osteocalcin, and MMP13 was decreased in transgenic
mice. By using RT-PCR, we also examined the expression
of  receptor activator of NF- B ligand  (RANKL)  and  os-
teoprotegerin (OPG), which are important for osteoclasto-
genesis and osteoclast activity. In transgenic mice, OPG
was decreased only slightly at 1 mo of age, but both
RANKL and OPG were decreased clearly at 3 mo of age.
Discussion
Cbfa1 transgenic mice showed severe osteopenia and suf-
fered from multiple fractures. Although trabecular bone was
conserved, cortical bone was reduced severely. Cortical
bone, which is composed of immature bone with a few os-
teocytes, was invaded by osteoclasts. Enlarged bone marrow
cavity also implied the osteolysis of cortical bone by osteo-
clasts. However, osteoclastogenesis was not accelerated in
transgenic mice. Osteoblast number was increased from an
early developmental stage, but osteoblast function was im-
paired in both matrix production and mineralization. Os-
teoblast maturation was inhibited at a late stage, and less
mature osteoblasts accumulated to form the impaired bone
in adult mice. Therefore, failure in the terminal differentia-
tion of osteoblasts resulted in osteopenia and fragility in
transgenic mice, demonstrating that Cbfa1 inhibits osteo-
blast differentiation at a late stage.
Previous in vitro and in vivo data suggested that Cbfa1
plays an important role in maturation of osteoblasts. How-
ever, our data showed that the late stage of osteoblast matu-
ration was inhibited in transgenic mice as indicated by the
accumulation of osteopontin-positive cells and the decrease
of highly osteocalcin-positive cells, osteocytes, and ALP and
osteocalcin expression. The accumulation of less mature os-
teoblasts in transgenic mice seemed to be caused not only by
the maturational blockage of osteoblasts but also by accelera-
tion of osteoblast differentiation at an early stage of cell de-
velopment because osteoblasts were increased in number at
neonatal stage (Fig. 8). Furthermore, the proliferation and
apoptosis of less mature osteoblasts in transgenic mice have
to be considered, although their analyses in vitro were un-
successful because of the loss of the transgene expression in
Figure 8. Maturational stage of osteoblasts in Cbfa1 transgenic 
mice. To determine the maturational stage of osteoblasts, sections 
from tibiae of wild-type (A, C, E, G, I, K, M, and O) and transgenic 
(B, D, F, H, J, L, N, and P) mice at birth (A–H) and 3 m of age (I–P) 
were examined by in situ hybridization using type I collagen (A, B, 
I, and J), osteopontin (C, D, K, and L), osteocalcin (E, F, M, and N), 
and Cbfa1 (G, H, O, and P) probes. The Cbfa1 probe detects the ex-
pression of endogenous Cbfa1 but not the transgene. Note that the 
pattern of Cbfa1 expression is similar to that of osteopontin expres-
sion but not osteocalcin expression in wild-type mice (C, E, G, K, M, 
and O). Osteopontin-positive cells are increased markedly, but 
osteocalcin highly positive cells are decreased markedly in trans-
genic mice (K, L, M, and N). Ct, cortical bone; Tb, trabecular bone. 
Bars: (A–H) 200  m; (I–P) 100  m.
Figure 9. Expression of genes related to bone matrix, mineraliza-
tion, and osteoclastogenesis. RNA was extracted from long bones 
without fractures at 4 wk of age for Northern blot analysis and at 4 
and 11 wk of age for RT-PCR. 20  g of total RNA was loaded and 
hybridized with probes of pro- 1 (I) collagen (Col1(I)), osteocalcin 
(OC), MMP13, ALP, bone sialoprotein (BSP), and osteopontin (OP). 
Glyceraldehyde-3-phosphate-dehydrogenase was used as an inter-
nal control. Representative data from four independent samples are 
shown. The expression of pro-  2(I) collagen (Col2(I)), RANKL, and 
OPG was examined by RT-PCR. HPRT was used as an internal 
control. Duplicate PCRs were performed in four independent 
samples. Representative data are shown. WT, wild-type mouse; Tg, 
transgenic mouse.164 The Journal of Cell Biology | Volume 155, Number 1, 2001
primary culture of calvaria-derived cells (unpublished data)
as previously described (Krebsbach et al., 1993).
ALP activity is detected at an early stage of osteoblast dif-
ferentiation and continues to increase during osteoblast mat-
uration until the mineralization phase (Stein et al., 1990;
Weinreb et al., 1990). In vitro experiments demonstrated
that Cbfa1 transfection induced ALP activity in multipoten-
tial mesenchymal cells, C3H10T1/2 and C2C12 (Harada et
al., 1999; Lee et al., 2000), indicating an important role for
Cbfa1 in the induction of ALP activity. Although the differ-
ence in ALP expression level between transgenic and wild-
type mice was not apparent at birth, it became evident dur-
ing development (Fig. 9; unpublished data). This suggests
that overexpression of Cbfa1 blocks osteoblast maturation at
a certain stage in vivo.
Since osteocalcin expression is restricted to mature osteo-
blasts and odontoblasts, it is a convenient marker for fully dif-
ferentiated osteoblasts (Mark et al., 1988; Stein et al., 1990).
Cbfa1 induced osteocalcin expression in various cells in vitro in-
cluding MC3T3-E1, C3H10T1/2, and skin fibroblasts (Ducy
et al., 1997; Harada et al., 1999). Furthermore, Cbfa1 or re-
lated proteins bound osteocalcin promoter and strongly in-
duced osteocalcin promoter activity in various cell lines, in-
cluding C3H10T1/2 and nonosteoblastic cells, HeLa and F9,
and Cbfa1 binding sites, were essential for osteocalcin expres-
sion (Geoffroy et al., 1995; Banerjee et al., 1996; Frendo et al.,
1998; Javed et al., 1999; Xiao et al., 1999). These findings sug-
gested that Cbfa1 is the most important factor for osteoblast-
specific osteocalcin expression in vitro. However, a major popu-
lation of Cbfa1 highly positive cells consisted of less mature
osteoblasts in wild-type mice, and overexpression of Cbfa1
failed to upregulate osteocalcin expression in vivo (Figs. 8 and
9). These data indicate that other factors, which are induced at
a late stage of osteoblast differentiation, are required for the
regulation of osteocalcin expression or that some factors sup-
press osteocalcin expression at an immature stage of osteoblast
differentiation in vivo. It has been shown that Groucho/TLE
proteins repress Runx-dependent activation of tissue-specific
gene transcription (Levanon et al., 1998; Javed et al., 2000),
and TLE downregulates Cbfa1-mediated activation of osteocal-
cin expression (Javed et al., 2000). Further, Runx1 is known to
interact with the corepressor mSin3A (Lutterbach et al., 2000).
Thus, these repressors may play an important role in the tran-
scriptional regulation of osteocalcin by repressing Cbfa1-depen-
dent activation at an early stage of osteoblast differentiation.
Overexpression of DN-Cbfa1 at a late stage of osteoblast
differentiation caused a decrease in the bone formation rate
and decreased expression of the genes encoding main bone
matrix proteins and resulted in osteopenia (Ducy et al., 1999).
Surprisingly, our transgenic mice overexpressing Cbfa1 at
both early and late stages of osteoblast differentiation also
showed an osteopenic phenotype, although the mechanism
for osteopenia was different. The two kinds of transgenic mice
had a common feature because Cbfa1 function was sup-
pressed in fully differentiated osteoblasts of DN-Cbfa1 trans-
genic mice, and the fully differentiated osteoblasts were di-
minished in our Cbfa1 transgenic mice. Therefore, both
transgenic mice lacked at least Cbfa1-dependent function of
fully differentiated osteoblasts, which finally caused osteope-
nia in both transgenic mice. It indicates that Cbfa1 inhibits
osteoblast differentiation at a late stage, but some level of
Cbfa1 is required for the expression of the genes encoding
main bone matrix proteins. It also indicates that the transcrip-
tional regulation of bone matrix genes by Cbfa1 is dependent
on the maturational stage of osteoblasts as discussed about os-
teocalcin expression in the previous paragraph.
It was reported recently that RANKL is essential for os-
teoclastogenesis and that OPG inhibits osteoclastogenesis
(Aubin and Bonnelye, 2000), and it was suggested that
Cbfa1 is involved in the regulation of RANKL or OPG ex-
pression (Gao et al., 1998; Kitazawa et al., 1999; Thir-
unavukkarasu et al., 2000). However, both RANKL and
OPG decreased gradually during development in transgenic
mice (Fig. 9). It was suggested that osteoprogenitor cells
have more potential to support osteoclast development than
more differentiated cells (Manolagas, 2000). Therefore, the
decrease of RANKL may reflect the relative decrease of os-
teoprogenitor cells because Cbfa1 seemed to accelerate the
early stage of osteoblast differentiation (Fig. 8). In transgenic
mice, cortical bone mass but not trabecular bone mass was
reduced severely without acceleration of osteoclastogenesis.
However, the enlarged bone marrow cavity and the presence
of numerous osteoclasts in cortical bone showed that cortical
bone loss was a result of osteolytic activity. This seemed to
be caused by the immature composition of cortical bone,
which contains abundant osteopontin with the small cell at-
tachment motif Arg-Gly-Asp recognized by integrins and
promotes the attachment of osteoclasts to the extracellular
matrix (Fig. 5; Young et al., 1993). The expression of bone
sialoprotein, which also has the Arg-Gly-Asp motif, was in-
creased in Northern blot analysis (Fig. 9). 
The drastic decrease of osteocytes that is a unique pheno-
type of the transgenic mice was caused by the inhibition
of osteoblast maturation. Osteocytes are spaced regularly
throughout the bone and communicate with each other and
with osteoblasts and bone marrow stromal cells using their
processes. Although the exact function of osteocytes re-
mains unknown, they are considered to work as mecha-
nosensors (Nijweide et al., 1996). Thus, the fragility of
transgenic bone might be caused by the near absence of os-
teocytes, causing an inability to detect mechanical stress
and microfractures. 
Overexpression of Cbfa1 in osteoblasts increased osteo-
blast number but inhibited their terminal maturation, re-
sulting in accumulation of less mature osteoblasts and os-
teopenia. Therefore, in an attempt to increase bone mass by
Cbfa1 intermittent induction of Cbfa1 in osteogenic cells
might permit a periodic increase of immature osteoblasts
and their maturation. This concept might be related to the
anabolic action on bone mass induced by the intermittent
administration of parathyroid hormone (Dempster et al.,
1993; Ishizuya et al., 1997; Jilka et al., 1999) because para-
thyroid hormone induces a protein kinase A–dependent
transactivation of Cbfa1 (Selvamurugan et al., 2000).
We demonstrated using Cbfa1 transgenic mice that Cbfa1
negatively regulates osteoblast differentiation at a late stage of
osteoblast development. However, Cbfa1 seems to regulate
osteoblast differentiation positively at an early stage. These
opposite functions of Cbfa1, depending on the maturational
stage of osteoblasts, may play an important role in the regula-Osteopenia in Cbfa1 transgenic mice | Liu et al. 165
tion of bone mass. Since Cbfa1 is an essential factor for os-
teoblast differentiation, many factors and substances that
have an effect on bone mass will influence Cbfa1 expression
or activation. Thus, our findings are expected to be of great
benefit to future trials to increase bone mass.
Materials and methods
Generation of transgenic mice
A DNA fragment covering the entire coding region of the mouse type II
Cbfa1 isoform (Harada et al., 1999) was cloned into the mammalian ex-
pression vector pNASS  (CLONTECH Laboratories, Inc.) by replacing the
 -galactosidase gene at NotI sites, giving rise to an intermediate vector for
inserting a promoter. A DNA fragment containing the 2.3-kb osteoblast-
specific promoter region for the mouse pro- 1 (I) collagen (Rossert et al.,
1995), which was provided by B. de Crombrugghe (The University of
Texas, Houston, Texas), was inserted into XhoI site of the intermediate vec-
tor to generate the final expression construct. The fragments from the final
construct, including the 2.3-kb pro- 1 (I) promoter and Cbfa1, were in-
jected into the pronuclei of fertilized eggs from C57BL/6   C3H F1
(B6C3H F1) mice. Transgene integration and expression were identified by
Southern and Northern blot analyses, respectively, using the whole length
cDNA of type II Cbfa1 as a probe. A transgenic line was maintained on a
B6C3H F1 background.
Detection of  -galactosidase activity
To confirm the activity of the promoter used in this study, we also sub-
cloned the DNA fragment covering the 2.3-kb pro- 1 (I) promoter region
into the EcoRI site of pNASS  to direct the expression of the  -galactosi-
dase gene. The  -galactosidase transgenic embryos were analyzed at dif-
ferent days postcoitum. Detection of  -galactosidase activity was per-
formed as described (Ueta et al., 2001). Stained embryos were embedded
in paraffin and used to generate 7- m sections, which were counterstained
with eosin.
X-ray and pQCT analyses
Transgenic mice and their wild-type littermates were anesthetized and
subjected to x-ray exposure in a micro-FX1000 (Fuji Film, Inc.). Long
bones were dissected from killed mice and exposed to x-rays. In pQCT
analysis, femurs were fixed with 10% buffered formalin for 24 h and mea-
sured using an XCT Research SA (Stratec Medizintechnik). Voxel size was
0.08   0.08   0.46 mm. The contour of the total bone was determined
automatically by the pQCT software algorithm. The cortical and trabecular
parameters were obtained at the diaphysis and 2 mm from distal epiphysis,
respectively. The threshold values of 690 mg/cm
3 for the cortical region
and 395 mg/cm
3 for the trabecular region were used in this experiment.
Histological analyses
For histological analyses, mice were killed at birth, 2 wk, 3 wk, 4 wk, 6
wk, 3 mo, 8 mo, and 1 yr of age. For the assessment of dynamic histomor-
phometric indices, mice were injected twice with calcein at a dose of 0.16
mg/10 g body weight and analyzed at 3 or 6 wk of age. The 3-wk group re-
ceived dual injections at 6 and 3 d before sacrifice, and the 6-wk group re-
ceived them at 8 and 1 d before sacrifice. Long bones were fixed with eth-
anol, and the undecalcified bones were embedded in glycolmethacrylate.
3- m longitudinal sections from the proximal parts of tibiae and 20- m
cross sections from mid-diaphyses of femurs were stained with toluidine
blue and analyzed using a semiautomated system (Osteoplan II; ZEISS).
Nomenclature, symbols, and units used are those recommended by the
Nomenclature Committee of the American Society for Bone and Mineral
Research (Parfitt et al., 1987). Some of the sections were stained with
TRAP. Bones from the other mice were fixed in 4% paraformaldehyde/0.1 M
phosphate buffer. Decalcified and paraffin-embedded sections (5  m
thick) were used for the following analyses. To examine collagen fiber
deposition, sections from tibiae were stained with hematoxylin and eosin
and observed under polarized light (Bucay et al., 1998). To examine osteo-
blast markers, sections of tibiae at different ages were also used for in situ
hybridization using probes for type I collagen, osteopontin, osteocalcin,
and Cbfa1 as described previously (Inada et al., 1999).
Immunohistochemistry
Paraffin sections were blocked with 1% BSA containing 10% swine or rab-
bit serum at room temperature for 20 min and then incubated with rabbit
anti–mouse osteopontin antibody (IBL Co., Ltd.) overnight at 4 C. Localiza-
tion of the first antibody was visualized by incubation with biotinylated
F(ab)2 fragments of swine anti–rabbit IgG antibody (Dako) at room temper-
ature for 40 min and then treated with the ABC reagents (Vector Laborato-
ries). Finally, sections were stained by DAB substrate and counterstained
with methyl green.
Northern blot and RT-PCR
Total RNA was extracted from long bones without fracture from newborn
and 4- and 11-wk-old transgenic and wild-type mice by lithium chloride.
20 Mg of total RNA was denatured with formamide, subjected to electro-
phoresis on 1.0% agarose gels, and transferred onto nylon membranes.
Membranes were hybridized with 
32P-labeled cDNA probes of pro- 1 (I)
collagen, osteocalcin, MMP13, ALP, osteopontin, bone sialoprotein, and
glyceraldehyde-3-phosphate-dehydrogenase  as described previously (In-
ada et al., 1999). For RT-PCR, cDNA was amplified by Amp Taq DNA
polymerase (PerkinElmer) using the following primers: Pro- 2 (I) collagen,
5 -TGTGCTTCTGCAGGGTTCCA-3  and 5 -ACACGGAATTCTTGGTC-
AGC-3 ; RANKL, 5 -GTCACTCTGTCCTCTTGGTAC-3  and 5 -TGAAAC-
CCCAAAGTACGTCG-3 ;  OPG, 5 -CAGCTTCTTGCCTTGATGGAGA-3 
and 5 -AAACAGCCCAGTGACCATTCCT-3 ; hypoxanthine guanine phos-
phoribosyl transferase (HPRT), 5 -GCTGGTGAAAAGGACCTCT-3  and 5 -
CACAGGACTAGAACAACTGC-3 . 18 (pro- 2 (I) collagen), 27 (RANKL),
28 (OPG), and 23 cycles (HPRT) of amplification were done with a Gene
Amp PCR system 2400 (Perkin Elmer) (30 s at 94 C, 30 s at 55 or 60 C, and
30 s at 72 C).
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